KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Gains from Sales and Divestitures (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 12 years of Gains from Sales and Divestitures data on record, last reported at $1.2 million in Q4 2024.

  • For Q4 2024, Gains from Sales and Divestitures rose 12.32% year-over-year to $1.2 million; the TTM value through Dec 2024 reached $1.2 million, up 12.32%, while the annual FY2024 figure was $1.2 million, 12.32% up from the prior year.
  • Gains from Sales and Divestitures reached $1.2 million in Q4 2024 per IONS's latest filing, up from $1.1 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.2 million in Q4 2024 and bottomed at $602000.0 in Q4 2020.
  • Average Gains from Sales and Divestitures over 5 years is $926800.0, with a median of $958000.0 recorded in 2022.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 42.65% in 2020, then rose 10.13% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $602000.0 in 2020, then surged by 38.54% to $834000.0 in 2021, then grew by 14.87% to $958000.0 in 2022, then rose by 10.13% to $1.1 million in 2023, then increased by 12.32% to $1.2 million in 2024.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $1.2 million in Q4 2024, $1.1 million in Q4 2023, and $958000.0 in Q4 2022.